Dr. Jae Park on Impact of Disease Burden on CAR T-Cells in Relapsed B-ALL

June 10, 2016
Jae Park, MD

Jae Park, MD, Hematologic Oncologist, Memorial Sloan Kettering Cancer Center, discusses the impact that disease burden plays on how adult patients with relapsed precursor B acute lymphoblastic leukemia (B-ALL) respond to cd19-targeted CAR modified T-cells.

Heavily pretreated B-ALL patients have demonstrated a remarkable response rate of 80% with cd19-targeted CAR modified T-cells, says Park. Disease burden does not impact how well the CAR-T cells work.

However, the side effects of CAR T- cells do differ depending on disease burden. The more disease a patient has, the more likely they are to experience toxicities, says Park.

The role of a bone marrow transplant for patients that have received CAR-T cells is also being investigated, says Park.

While the results are not definitive, researchers have found that patients with either low or high disease burden who have receive CAR-T cells and achieved a good remission do not appear to benefit form a bone marrow transplant, says Park.


View more from the 2016 EHA Congress